The China Tuberculosis Association and Fosun Foundation and Hongqi Pharmaceutical jointly launched the "Double Thousand Action" project, and officially launched the 2016 World Tuberculosis Day publicity campaign
March 24, 2016 is the 21st World Tuberculosis Day. my country’s propaganda theme is "Society work together to eliminate the hazards of tuberculosis". In 2015, the World Health Organization put forward the goal of ending global tuberculosis by 2035, and the Chinese government also put forward the goal of universal health and poverty eradication. To this end, the China National Defence Tuberculosis Association established the "China National Defence Tuberculosis Public Welfare Fund" and, together with the Fosun Public Welfare Foundation, and Fosun Pharma’s member company Shenyang Hongqi Pharmaceutical Co., Ltd. ("Hongqi Pharmaceutical") jointly launched the China National Defence Tuberculosis Public Welfare Fund— -"Double Thousand Action" project for tuberculosis poverty relief.
On March 22, 2016, the "Double Thousand Action" project was announced at the theme publicity event of World Tuberculosis Day jointly sponsored by the National Health and Family Planning Commission and the Beijing Municipal People's Government. On the same day, Peng Liyuan, Goodwill Ambassador for Tuberculosis/AIDS Prevention and Control of the World Health Organization, was invited to participate in the event, and distributed health packs to migrant workers in the city, and expressed condolences to the medical workers and migrant workers who participated in the free clinic on the spot.
The "Double Thousand Action" project started in 2016 and lasted for five years from 2020. It can save at least 1,000 poor tuberculosis patients each year, and each patient's assistance fund is at least 1,000 yuan. The Fosun Charity Foundation and Hongqi Pharmaceutical, a member company of Fosun Pharma, will continue to support this project by providing funding, medicines and other forms of sponsorship.
The Fosun Charity Foundation was formally established on the 20th anniversary of the establishment of Fosun Group in September 2012, adhering to the group’s cultural philosophy of “self-cultivation, family, career, and helping the world”, and its purpose is to inherit culture, support education, and encourage youth entrepreneurship , Spread the concept of health, disaster relief, etc. Shenyang Hongqi Pharmaceutical Co., Ltd. ("Hongqi Pharmaceutical" for short) is a member company of Fosun Pharma and has become the country's largest anti-tuberculosis drug R&D and production base.
In order to build a production base for anti-tuberculosis drugs in China, Hongqi Pharmaceutical has gone through several generations of hard work. At present, its first-line anti-tuberculosis drugs are Rifampicin Capsules, Rifampicin Capsules II, Isoniazid Tablets, Ethambutol Tablets (Capsules), Pyrazinamide Tablets (Capsules), Prothionamide Enteric-coated Tablets, etc. Sales have always been in the forefront of the country. In particular, FDC (Fixed Dose Combination) products have two kinds of medicines taken daily and every other day. At present, Hongqi Pharmaceutical Company's anti-tuberculosis drugs have been serialized, which has made important contributions to the treatment of tuberculosis in China and the world. In particular, the emergence of FDC has met the needs of standardized treatment and provided great convenience for the procurement of free drugs for disease control in my country. At the same time, it is also a powerful weapon to encourage patients to take medication regularly.
In terms of multi-drug-resistant tuberculosis, Hongqi Pharmaceutical independently develops new drugs such as Lichen Maidi tablets, and also acts as an agent for cycloserine capsules and capreomycin; it is currently introducing second-line high-end tuberculosis drugs such as bedaquiline tablets.
Tuberculosis is an infectious disease that seriously endangers the health of our people, and it is also one of the diseases that our government focuses on. Tuberculosis is still one of the important causes of "poverty due to illness and return to illness due to poverty" in some families. Hongqi Pharmaceutical, a member company of Fosun Pharma, will spare no effort to support China's anti-tuberculosis cause and continue to innovate good products to serve patients. The "Double Thousand Action" project was officially launched today! We hope to arouse caring companies and people from all walks of life to actively join the donation team of the China National Tuberculosis Public Welfare Fund to benefit more tuberculosis patients and families. Through such public welfare actions, we can influence more forces in society to work together to achieve global tuberculosis end The goal!
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharmaceutical" for short, stock code: 600196-SH, 02196-HK) was established in 1994 and is a leading medical and health industry group in China.